23 Jan 2022 , 07:34 PM
During the quarter, the company saw 10% revenue growth in the core market comprising of US, Canada, EU and Australia at Rs665cr. The India revenues were 31% higher yoy at Rs195cr while revenues from the rest of the world were up 88% at Rs203cr.
Total R&D expenses stood at 6.6% of revenues. In Q3, Gland filed 18 ANDAs and 3 DMFs and got 4 ANDA approvals.
EBITDA was up 32% yoy at Rs395cr in the third quarter. Net margins expanded from 23.75% in the Dec-20 quarter to 25.68% in the Dec-21 quarter. Net margins were lower sequentially by 228 basis points.
Financial highlights for Dec-21 compared yoy and sequentially
Gland Pharma | |||||
Rs in Crore | Dec-21 | Dec-20 | YOY | Sep-21 | QOQ |
Total Income (Rs cr) | ₹ 1,063.33 | ₹ 859.42 | 23.73% | ₹ 1,080.47 | -1.59% |
Net Profit (Rs cr) | ₹ 273.03 | ₹ 204.11 | 33.77% | ₹ 302.08 | -9.62% |
Diluted EPS (Rs) | ₹ 16.62 | ₹ 12.82 | ₹ 18.37 | ||
Net Margins | 25.68% | 23.75% | 27.96% |
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.